Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
TCRX
TCRX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
TCRX News
TScan Therapeutics Q4 Earnings Beat Expectations
6d ago
seekingalpha
TScan Completes Enrollment in ALLOHA™ Trial Cohort C
Feb 26 2026
Newsfilter
GT Biopharma Advances GTB-3650 Clinical Trial to Cohort 4 with 10μg/kg/day Dosing
Dec 19 2025
PRnewswire
GT Biopharma Advances GTB-3650 Clinical Trial to Cohort 4 with 10μg/kg/day Dosing
Dec 19 2025
Newsfilter
TScan Reports 100% Relapse-Free Survival in AML Patients Treated with TSC-101 at Two-Year Follow-Up
Dec 06 2025
Globenewswire
TScan's TSC-101 Shows Significant Efficacy in Cancer Treatment
Dec 06 2025
Newsfilter
GT Biopharma Completes Safety Review for GTB-3650 Phase 1 Trial
Dec 04 2025
Newsfilter
GT Biopharma Completes Safety Review for GTB-3650 Phase 1 Trial
Dec 04 2025
PRnewswire
TScan Therapeutics Set to Update on Phase 1 Trial of TSC-101 for Hematologic Cancers Next Week
Dec 04 2025
NASDAQ.COM
TScan Hosts KOL Event to Discuss ALLOHA Trial Data and Market Opportunities
Dec 03 2025
Globenewswire
TScan Hosts KOL Event to Discuss ALLOHA Trial Data and Market Opportunities
Dec 03 2025
Newsfilter
Biotech Stocks Rise After Hours: Clene Jumps Ahead of ALS Update; Werewolf, Biomea, and Dyne Also Gain
Dec 03 2025
NASDAQ.COM
TScan Therapeutics, Inc. Reports Wider Q3 Loss, Yet Surpasses Expectations
Nov 12 2025
NASDAQ.COM
Kimberly-Clark Analyst Changes Stance; Check Out Tuesday's Top 5 Downgrades
Nov 04 2025
Benzinga
Needham Keeps Buy Rating on TScan Therapeutics, Reduces Price Target to $6
Nov 04 2025
Benzinga
TScan Therapeutics Secures FDA Agreement on Key Study Design for TSC-101 and Reveals Strategic Focus to Propel TSC-101 Development While Extending Cash Runway Through H2 2027
Nov 03 2025
Newsfilter
Show More News
